Endometrial Clinical Trials
Delivering quality care through clinical trials
Available clinical trials are below. Click the + sign to expand and review details about their purpose, eligibility criteria, and contact information for study staff. For some studies, you will find a link to ClinicalTrials.gov, where you can explore more information about each study.
NRG - NRG-GY026
Study Phase: Phase II/III - Drug
Condition(s): Stage I-IV endometrial cancer
Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Herceptin Hylecta or Pertuzumab, Trastuzumab and PHESGO in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
ClinicalTrials.gov NCT ID: NCT05256225
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
Merck MK2870-33
Study Phase: Phase III - drug
Condition(s): Stage III or IV endometrial cancer
A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033)
ClinicalTrials.gov NCT ID: NCT06952504
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
To inquire if you're eligible for a clinical trial, contact: (484) 658-5080, or click here to complete a clinical trial inquiry form.
